Suppr超能文献

外周血值和骨髓表现对原发性血小板增多症和真性红细胞增多症患者预后的影响。

The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera.

机构信息

Hematology and Coagulation Section, Department of Medicine, Sahlgrenska University Hospital, Göteborg, Sweden.

出版信息

Eur J Haematol. 2011 Feb;86(2):148-55. doi: 10.1111/j.1600-0609.2010.01548.x. Epub 2010 Dec 22.

Abstract

The Philadelphia chromosome-negative (Ph-) chronic myeloproliferative neoplasms include the three well-known clinical entities polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Over time, patients with ET and PV may develop myelofibrosis (MF), and all three entities carry a risk of transformation into acute myeloid leukemia (AML). In a population-based survey during 1983-1999, we studied a total of 358 patients who were diagnosed with ET and PV in the city of Gothenburg, Sweden. At the time of diagnosis, evaluable bone marrow biopsy material was available from 280 of these patients. The current work was aimed at investigating the impact of peripheral blood counts, spleen size, and bone marrow biopsy findings at diagnosis on long-term survival and the risk of development of AML or MF in this well-defined unselected population. The variables evaluated were venous blood hemoglobin concentration, packed cell volume, white blood cell count, platelet count, and splenic enlargement; as to bone marrow biopsies, interest was focused on reticulin content, focal or generalized collagen formation, bone marrow cellularity, and megakaryocyte profile number. Over the median observation time of 15 yr, the patients with ET did not demonstrate any significant difference as to survival compared to the normal Swedish population (hazard ratio, 1.23; 95% confidence interval, 0.97-1.51; p= 0.089). The patients with PV, on the other hand, had a significantly shorter survival compared to general population (hazard ratio, 1.66; 95% confidence interval, 1.38-1.99; p< 0.001). A lower hemoglobin concentration at diagnosis of ET predicted poorer survival (p =0.0281), whereas patients with PV with splenic enlargement at diagnosis had a shorter survival (p =0.037). In the patients with ET, the risk of transformation to either MF or AML was significantly associated with low hemoglobin concentration and high white cell count at diagnosis (p =0.0037 and 0.0306, respectively). An increased reticulin content and hypercellularity in the bone marrow at diagnosis were also independent risk factors (p =0.0359 and 0.0103, respectively). The risk of transformation in patients with PV was significantly associated with splenic enlargement and increase in bone marrow reticulin content (p =0.0028 and 0.0164, respectively).

摘要

费城染色体阴性(Ph-)慢性骨髓增殖性肿瘤包括三种众所周知的临床实体:真性红细胞增多症(PV)、特发性血小板增多症(ET)和原发性骨髓纤维化(PMF)。随着时间的推移,ET 和 PV 患者可能会发展为骨髓纤维化(MF),所有这三种实体都有转化为急性髓系白血病(AML)的风险。在 1983 年至 1999 年期间进行的一项基于人群的调查中,我们研究了在瑞典哥德堡市诊断为 ET 和 PV 的总共 358 名患者。在这些患者中,有 280 名患者在诊断时可评估骨髓活检材料。目前的工作旨在研究外周血细胞计数、脾脏大小和诊断时骨髓活检结果对该明确未选择人群的长期生存和 AML 或 MF 发展风险的影响。评估的变量包括静脉血血红蛋白浓度、红细胞压积、白细胞计数、血小板计数和脾脏肿大;至于骨髓活检,重点关注网状纤维含量、局灶性或弥漫性胶原形成、骨髓细胞增生度和巨核细胞形态数量。在中位观察时间 15 年内,与瑞典正常人群相比,ET 患者的生存无显著差异(危险比,1.23;95%置信区间,0.97-1.51;p=0.089)。另一方面,PV 患者的生存明显短于普通人群(危险比,1.66;95%置信区间,1.38-1.99;p<0.001)。ET 患者诊断时血红蛋白浓度较低预示着生存较差(p=0.0281),而诊断时有脾脏肿大的 PV 患者生存时间较短(p=0.037)。在 ET 患者中,向 MF 或 AML 转化的风险与诊断时低血红蛋白浓度和高白细胞计数显著相关(p=0.0037 和 0.0306)。诊断时骨髓网状纤维含量增加和细胞增生也是独立的危险因素(p=0.0359 和 0.0103)。PV 患者的转化风险与脾脏肿大和骨髓网状纤维含量增加显著相关(p=0.0028 和 0.0164)。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验